With Robert F. Kennedy Jr. tapped to run Health and Human Services under President Trump, a lot of people are asking the same question: What happens now? And more importantly, can our healthcare system bounce back from whatever this new administration puts in place? What People Are Worried About The worries are pretty straightforward. Kennedy’s…
If a Trump-era trade deal with the UK focused on pharmaceuticals ever gets off the ground, it won’t be just another agreement. It would be a head-on collision between two completely different ways of thinking about healthcare: one where market price is king, and another built around what the nation can afford. The outcome would…
For years, one of the most common refrains in the U.S. drug pricing debate has been simple: Americans subsidize the world’s healthcare. The argument goes that if other wealthy nations—particularly in Europe—paid more for their medications, U.S. prices would naturally fall. It’s an appealing narrative, but the reality is far more complicated. The truth is…
For as long as we’ve known about Alzheimer’s, a diagnosis has felt like a one-way street, a devastating journey of losing memories, independence, and a sense of self. For decades, treatments could only chip away at the symptoms, offering little to slow the disease itself. But now, a new wave of drugs is trying to…
With prices for drugs like Ozempic and Wegovy finally coming down, they’re becoming a real option for millions of people looking to lose weight. It’s a game-changer for anyone who’s struggled with obesity, but a surprising truth is popping up in doctors’ offices and online forums: the shot is only half the battle. Lots of…
The relationship between your doctor and pharma companies has never been more complicated. While you’re sitting in the waiting room, scrolling through health information on your phone, a cheerful TV commercial shows happy people hiking mountains and playing with their grandchildren—all thanks to a medication whose side effects scroll past in rapid-fire legalese. This is…
Robert F. Kennedy Jr. is a polarizing figure, particularly on health issues. But even a stopped clock is right twice a day. On one core claim, Kennedy has identified something many Americans already know from painful experience: the U.S. healthcare system is profoundly, systematically broken. Strip away the more controversial aspects of Kennedy’s health rhetoric,…
The pharmaceutical industry has found its latest darling: GLP-1 receptor agonists. Originally developed for Type 2 diabetes, drugs like Ozempic, Wegovy, and Mounjaro have become cultural phenomena, promising not just blood sugar control but significant weight loss. Wall Street has taken notice, with some analysts projecting the GLP-1 market could reach $100 billion or more…
They should have seen it coming. Maybe they did see it coming. But when you’re in the trenches—pulling 60-hour weeks, celebrating those FDA approvals at 11 PM via Zoom, watching your pipeline drug finally hit commercialization targets—you tell yourself this time will be different. It wasn’t. Last Tuesday, they got the calendar invite. You know…
There’s a quiet but troubling shift happening in the halls of biotech companies right now, and it’s not getting nearly the attention it deserves. While the FDA grapples with leadership gaps, budget constraints, and an overloaded review calendar, some biotech executives see the chaos not as a regulatory risk—but as an opportunity. They’re treating FDA…